FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

4 FDA/ECRI Material Safety Summaries Out

[ Price : $8.95]

FDA releases four medical device material safety summaries developed through a partnership with ECRI.

Cabometyx Approved for Thyroid Cancer

[ Price : $8.95]

FDA approves an Exelixis NDA for Cabometyx (cabozantinib) for treating certain adult and pediatric patients 12 years of age and ol...

Incyte sNDA for Graft-vs-host Disease OKd

[ Price : $8.95]

FDA approves an Incyte supplemental NDA for Jakafi (ruxolitinib) for treating chronic graft-versus-host disease after failure of o...

MITA Concerns With FDA Remanufacturing Guidance

[ Price : $8.95]

The Medical Imaging & Technology Alliance says an FDA draft guidance on medical device remanufacturing is not likely to be effecti...

ANDA for Hydroxyethyl Starch Withdrawn

[ Price : $8.95]

Federal Register notice: FDA withdraws approval of a B. Braun Medical ANDA for 6% hydroxyethyl starch after the company requested ...

Public Meeting on Biosimilar User Fee Reauthorization

[ Price : $8.95]

Federal Register notice: FDA announces an 11/2 virtual public meeting to discuss proposed recommendations for reauthorizing the Bi...

Paige Prostate AI Software Marketing Authorization

[ Price : $8.95]

FDA grants a de novo marketing authorization for Paige AIs Paige Prostate software that is intended to assist pathologists in dete...

FDA Defers Action on Humira Biosimilar

[ Price : $8.95]

FDA defers a review action on an Alvotech BLA for AVT02, the companys proposed biosimilar of AbbVies Humira (adalimumab) Humira, u...

Attorneys See Good Things in PDUFA 7 Goals

[ Price : $8.95]

Two Hyman, Phelps attorneys analyze the top 10 things they like in the FDA PUDFA 7 goals letter.

Prior Decisions Should Guide New Drug Reviews: Researchers

[ Price : $8.95]

Researchers writing in the Annals of Internal Medicine say FDA must find ways to improve institutional memory of drug review decis...